Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles

Citation

As Published
http://dx.doi.org/10.1073/pnas.1303377110

Publisher
National Academy of Sciences (U.S.)

Version
Final published version

Accessed
Sun Jun 18 04:13:00 EDT 2017

Citable Link
http://hdl.handle.net/1721.1/81300

Terms of Use
Article is made available in accordance with the publisher’s policy and may be subject to US copyright law. Please refer to the publisher’s site for terms of use.

Detailed Terms
Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles

Nazila Kamaly1,a, Gabrielle Fredman1,a, Manikandan Subramanianb, Suresh Gadde1, Aleksandar Pesic1, Louis Cheung1, Zahi Adel Fayad6, Robert Langer2,d,2, Ira Tabas2,b,2, and Omid Cameron Farokhzad2,c

1Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115; 2Departments of Medicine, Pathology and Cell Biology, and Physiology, Columbia University, New York, NY 10032; 3Translational and Molecular Imaging Institute, Mount Sinai School of Medicine, New York, NY 10029; and 4Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139

Contributed by Robert Langer, February 22, 2013 (sent for review December 20, 2012)

Excessive inflammation and failed resolution of the inflammatory response are underlying components of numerous conditions such as arthritis, cardiovascular disease, and cancer. Hence, therapeutics that dampen inflammation and enhance resolution are of considerable interest. In this study, we demonstrate the proresolving activity of sub-100-nm nanoparticles (NPs) containing the anti-inflammatory peptide Ac2-26, an annexin A1/hopocortin 1-mimetic peptide. These NPs were engineered using biodegradable diblock poly(lactic-co-glycolic acid)-b-polyethyleneglycol collagen IV–targeted polymers. Using a self-limited zymosan-induced peritonitis model, we show that the Ac2-26 NPs (100 ng per mouse) were significantly more potent than Ac2-26 native peptide at limiting recruitment of polymophonuclear neutrophils (56% vs. 30%) and at decreasing the resolution interval up to 4 h. Moreover, systemic administration of collagen IV targeted Ac2-26 NPs (in as low as 1 μg peptide per mouse) was shown to significantly block tissue damage in hind-limb ischemia-reperfusion injury by up to 30% in comparison with controls. Together, these findings demonstrate that Ac2-26 NPs are proresolving in vivo and raise the prospect of their use in chronic inflammatory diseases such as atherosclerosis.

acute inflammation | proresolving activity | nanomedicine | nanotechnology | controlled release | inflammation resolution

Acute inflammation is a protective response that combats invading organisms and repairs tissue injury (1). Ideally, this response is self-limited and leads to clearance of pathogens, cellular debris, and inflammatory mediators (1, 2). However, an excessive inflammatory response impairs resolution and leads to chronic inflammation and subsequent tissue damage (2–4). Increasing evidence suggests that excessive inflammation and impaired resolution play central roles in several prevalent diseases including cardiovascular, metabolic, and neurodegenerative diseases (5). Hence, development of therapeutics that temper inflammation and enhance resolution are of considerable interest (3, 4, 6).

Resolution processes are active endogenous counterregulatory processes that are orchestrated, in part, by specialized proresolving lipid mediators (SPMs) (4). Examples of SPMs include lipoxins, resolvins, protectins, maresins, and specific peptide mediators such as annexin A1 (4, 7). Bannenberg et al. introduced and defined quantitative resolution indices in vivo that allow for temporal regulation of leukocyte trafficking and chemical mediators within inflammatory exudates (8). These indices are the maximal neutrophil numbers that are present in the exudates ($\psi_{\text{max}}$), the time when $\psi_{\text{max}}$ occurs ($T_{\text{max}}$), and the resolution interval from $T_{\text{max}}$ to $T_{\text{50}}$ ($R_{50}$) — i.e., the time that it takes for the number of polymophonuclear neutrophils (PMNs) to reach half $\psi_{\text{max}}$ (8). Importantly, these indices not only provide a quantitative measure of the specific actions of endogenous SPMs and peptides but also provide a means to investigate whether pharmacologic agents can enhance or impair resolution (9–11). In this regard, only a few widely used therapeutics have been assessed for their impact in programmed resolution (9, 10, 12).

The application of nanotechnology to medicine (nanomedicine) is expected to have a profound impact on human health (13, 14). Nanoparticles (NPs) are an important class of nanomedicines, and many distinct NP platforms have been developed to successfully deliver bioactive molecules and imaging agents to sites of disease (15–19). Recently, SPMs incorporated into NPs derived from human PMNs were shown to limit acute inflammation, enhance resolution, and reduce joint damage (11). In this study, we investigated the delivery and bioactions of polymeric NPs encapsulating Ac2-26, an annexin A1 terminal 25 amino acid mimetic peptide that acts on the G-protein-coupled formyl peptide receptor, ALX/FPR2, which is also the receptor for lipoxin A4 (7, 20, 21). Ac2-26 exerts anti-inflammatory (22) and proresolving actions in vivo and was shown to be protective in several disease models, including myocardial ischemia-reperfusion injury (23), allergic inflammation (24), and endotoxin-induced cerebral inflammation (25).

Polymers are versatile building blocks for NP development as they can be custom-synthesized with unique biocompatibility and degradation properties (26). Their physicochemical properties can be easily manipulated, allowing for the development of self-assembled and customizable, controlled release therapeutic NPs (16, 27–29). We encapsulated Ac2-26 in targeted polymeric NPs to improve the pharmaceutical and pharmacological properties of Ac2-26 by enhancing its systemic circulation in vivo, site-specific delivery, and controlled release in a spatiotemporal manner. Additionally, we used a collagen IV (Col IV)-targeted heptapeptide ligand that we have previously identified by phage display (30). Because Coll IV represents 50% of the vascular basement membrane, we hypothesized that Coll IV exposure will occur at sites of vascular inflammation and injury (30, 31), enabling targeting of our NPs to sites of vascular injury. Here, we demonstrate that Ac2-26 NPs are proresolving in vivo and are significantly more potent than the Ac2-26 native peptide at blocking zymosan-stimulated PMN recruitment in an acute peritonitis model. Additionally, using a hind-limb ischemia-reperfusion model of vascular and tissue injury, we show that Col IV-targeted Ac2-26 NPs

Conflict of interest statement: O.C.F. discloses his financial interest in BIND Biosciences, Selecta Biosciences, and Blend Therapeutics, three biotechnology companies developing nanoparticle technologies for medical applications. BIND, Selecta, and Blend did not support the aforementioned research, and currently these companies have no rights to any technology or intellectual property developed as part of this research.

1N.K. and G.F. contributed equally to this work.
2To whom correspondence may be addressed. E-mail: ranger@mit.edu, iat1@bwh.harvard.edu, or ofarokhzad@zeus.bwh.harvard.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1303377110/-/DCSupplemental.
exert a tissue-restorative property. The proresolving targeted NPs developed in this study may prove beneficial for more chronic diseases in which excessive inflammation plays a critical role.

Results

Synthesis and Characterization of Targeted Ac2-26 Col IV NPs and Controls. The NPs were created via a single-step nanoprecipitation self-assembly method. In addition to nontargeted and Col IV-targeted Ac2-26 NPs, nontargeted and targeted NPs containing a randomly generated, isoelectric, mismatched scrambled sequence (Scrm Ac2-26) were also engineered (Fig. 1) to control for the biophysicochemical properties of the Ac2-26 peptide. In addition, some experiments used free Ac2-26 peptide in solution to compare

the additional anti-inflammatory benefits conferred by the encapsulation of Ac2-26 within NPs. To engineer polymeric NPs, copolymers of poly(lactic-co-glycolic acid)-b-polyethylene glycol (PLGA-PEG) and Col IV peptide-conjugated PLGA-PEG-collagen IV–targeted polymers and a fluorescent polymer were synthesized according to Fig. S1. The carboxy terminal of PLGA and the amino functionality of PEG were coupled using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) activation methodology to yield 1 (Fig. S1). The PLGA-PEG-COOH was then coupled to the heterobifunctional maleimide-PEG-hydroxy to yield PLGA-PEG-maleimide (PLGA-PEG-Mal) (2). The Col IV peptide-conjugated targeting polymer was then synthesized by conjugating the KLWVLPK peptide to PLGA-PEG-Mal via the free thiol of the C-terminal GGCG linker using maleimide chemistry. The product was purified and washed by precipitation in cold methanol to obtain 3 (Fig. S1). A fluorescent polymer was also synthesized by coupling carboxy terminaled PLGA to Alexa 647 cadaverine to give polymer 4 (Fig. S1). With the polymers in hand, and characterized by 1H NMR (Figs. S2–S5), the NPs were engineered, purified, and characterized. The hydrodynamic size of the various NPs in water were as follows: empty NPs, 58.1 ± 0.8 nm; Ac2-26 NPs, 62.1 ± 0.8 nm; Ac2-26 Col IV NPs, 76.3 ± 0.9 nm; Scrm Ac2-26 NPs, 68.4 ± 0.7 nm; and Scrm Ac2-26 Col IV NPs, 77.15 ± 1.1 nm (Fig. 2A). The surface charge of the NPs were as follows: empty NPs, −1.21 mV; Ac2-26 NPs, −28.77 ± 0.82 mV; Ac2-26 Col IV NPs, −19.68 ± 0.78 mV; Scrm Ac2-26 NPs, −30.71 ± 1.0 mV; and Scrm Ac2-26 Col IV NPs, −15.49 ± 0.84 mV (Fig. 2B). The Col IV-bearing NPs were larger than the nontargeted NPs (~8.75 nm for Ac2-26 Col IV NPs and ~14.2 nm for Scrm Ac2-26 Col IV NPs) and were also more positive in charge (~9.09 and ~15.22 mV, respectively). The increase in size is attributed to the increased bulk of the NPs bearing the Col IV-targeted peptide sequence, and the increase in positive charge may be due to the N-terminal exposed orientation of the peptide.

The peptide loading and release rates of the NPs were then measured. The loading of the peptide in the NPs was optimal up to 4% nominal loading (peptide/polymer wt/wt). At this ratio, the NPs were stable, and release could be optimally tuned. The size of the NPs was also kept at sub-100 nm for improved vessel adhesion and retention (32–35). The percentage encapsulation efficiency and loading were measured to be ~90% and 3.36%, respectively, for peptide-loaded NPs. The Ac2-26 NPs were optimized for sustained release, i.e., for up to a period no longer than 1 wk to facilitate a single weekly dosing regimen for future studies using chronic inflammatory disease models. The release kinetics of Ac2-26 from targeted and nontargeted NPs was measured by incubating the NPs at 37 °C and then measuring the released peptide in solution, which was isolated via ultracentrifugation. Released peptide concentrations were measured using UV spectroscopy, and a cumulative release curve was generated (Fig. 2C). The release of Ac2-26 from the NPs was found to be ~20% per day. Transmission electron microscopy (TEM) revealed that the targeted NPs were spherical and had uniform structure (Fig. 2D).

Proresolving Bioactions of Ac2-26 NPs in Vivo. To determine whether the developed NPs containing Ac2-26 are anti-inflammatory and/or proresolving, we used a model of self-limited peritonitis to quantitatively assess resolution in vivo (8, 9). C57BL/6d mice were administered 100 μg of zymosan A i.p. per mouse. In parallel, mice were then given vehicle, empty NPs, 100 ng per mouse Ac2-26 in NPs, 100 ng per mouse Scrm Ac2-26 in NPs, or 100 ng per mouse Ac2-26 native peptide. Equal polymer concentration was loaded in both the NPs and the Ac2-26 NPs. Ac2-26 NPs blocked zymosan-stimulated PMN infiltration by ~56% (P < 0.01), whereas freely administered Ac2-26 peptide blocked PMN infiltration by only ~30%, which did not reach statistical significance (Fig. 3). Empty
NPs did not exert a protective effect, indicating that the pro-
resolving action was a result of Ac2-26 and not the polymeric
composition of the NPs. The Ac2-26 scrambled peptide was also
not protective, confirming that the specific sequence of Ac2-26
peptide confers protective action. Flow cytometric analysis of
the peritoneal exudate cells showed that there were fewer PMNs in
the Ac2-26 NP-treated group (Fig. 3B, Lower) vs. the zymosan-alone
group (Fig. 3B, Upper).

Acute inflammation and its timely resolution are programmed
temporal events (3, 36). In this regard, resolution can be defined
at the histological level as the interval from maximum PMN in-
filtration to the point where PMNs are lost from the tissue (8).
Zymosan exhibited a self-limiting PMN curve with a maximal
PMN infiltration ($\psi_{\text{max}}$) of $\sim$4.3 x 10$^6$ PMNs, a $T_{\text{max}}$ of 12 h (Fig. 3C and D), and a resolution interval ($R_{\text{f}}$) of $\sim$12 h (Fig. 3C and D).
The scrambled Ac2-26 peptide did not block zymosan-stimulated
PMN infiltration at any time point. Notably, the free Ac2-26 peptide
was not used here because it did not significantly limit PMN
infiltration at the dose of 100 ng per mouse (Fig. 3A). Also, it is
already known that native Ac2-26 peptide exerts anti-inflammatory
actions and blocks PMN infiltration at higher doses in this model
(22). In contrast, NPs containing Ac2-26 (100 ng per mouse) sig-
ificantly blocked PMN infiltration at 4, 12, and 24 h post zymosan
challenge and exhibited a $\psi_{\text{max}}$ of $\sim$2.6 x 10$^6$ PMNs, a $T_{\text{max}}$ of 12 h,
and a $R_{\text{f}}$ of 8 h (Fig. 3C and D). Thus, Ac2-26 NPs enhanced
resolution 4 h faster than zymosan alone.

**Tissue Restorative Bioactions of Targeted Ac2-26 Col IV NPs in Vivo.**

Excessive accumulation of PMN within tissues can lead to tissue
damage, amplification, and prolongation of the inflammatory
response (1). Because we showed that Ac2-26 NPs limit PMN
infiltration in vivo (Fig. 3), we next sought to investigate the
actions of Ac2-26 NPs in a model of tissue injury driven by ex-
cessive PMN infiltration and activation (37) (Fig. 4). In this
regard, we chose a model of hind-limb ischemia reperfusion in
which a tourniquet was tied around the hind limbs of the mice for
1 h to induce ischemia. After 1 h, the tourniquet was removed,
and the mice were injected with vehicle, Ac2-26 NPs, Ac2-26 Col IV
NPs, or Scrm Ac2-26 Col IV NPs (each at 1 $\mu$g peptide or vehicle
equivalent per mouse). After 1 h of reperfusion, the mice were
euthanized, and the gastrocnemius muscle was harvested to assess
local tissue damage. Col IV is abundant in basement membranes
and is exposed upon injury (30, 31), and so we hypothesized that
the targeted NPs would home to the site of injury and release Ac2-
more efficiently than the nontargeted NPs. Indeed, Ac2-26 Col
IV NPs differentially localized to the injured tissue, compared
with nontargeted Ac2-26 NPs (Fig. 4A). Also, Ac2-26 Col IV NPs
limited PMN infiltration by $\sim$30%, whereas Ac2-26 NPs or
Scrm Ac2-26 Col-IV NPs had no inhibitory effect (Fig. 4B).
Thus, Ac2-26 Col IV NPs displayed a restorative action in this model
of tissue injury after only 1 h of postsystemic administration.

**Discussion**

Failed resolution of inflammation is the underlying component in
several prevalent diseases, and thus development of therapeutics
that enhance resolution are of considerable interest (3). In the
present report, we investigated the delivery and bioactions of
polymeric NPs containing the anti-inflammatory Ac2-26 peptide.
Our results demonstrate that Ac2-26 NPs can be encapsulated
successfully in sub-100-nm NPs, exhibit controlled temporal re-
lease, and exert potent proresolving actions in vivo, indicating that
they enhance endogenous resolution programs.

The polymeric NP design used in this study incorporated bio-
compatible, biodegradable, and bioeliminable materials and made
use of a self-assembly approach. Conventional methods of engi-
neering targeted NPs involve a series of synthetic coupling steps
involving the bioconjugation of targeting ligands to the surface of
preformed NP cores (26). This postcoupling of targeting ligands
requires excessive amounts of reagents to achieve high coupling
efficiencies and requires further NP purification techniques to
remove unbound ligands. As such, heterogeneity may arise in the
reproducibility of NP surface properties and ligand densities,
resulting in batch-to-batch variability, which may hinder success-
ful clinical translation and subsequent commercialization (26). The
design of prefuntionalized peptide-conjugated copolymers allows
for the reproducible creation of optimal targeted NPs, whereby
controlling the self-assembly and ratio of each constituent can lead to targeted polymeric NPs with precisely tuned biophysicochemical properties (29). The use of diblock hydrophobic-PEGylated polymers in nanoprecipitation leads to NPs that consist of a hydrophobic core, with entrapped therapeutics surrounded by a hydrophilic PEG shell for steric stabilization and prolonged systemic circulation (38). In nanoprecipitation, the instantaneous formation of particles is governed by the principles of the Marangoni effect and has been attributed to interfacial interactions between liquid phases (39). Nanoprecipitation is a simple method, amenable to scale-up at an industrial scale, and requires only mild mixing under minimal shear stress. In general, smaller NPs are obtained through this method compared with other methods under equivalent conditions.

The Ac2-26 NPs enhanced resolution 4 h sooner than vehicle treatment, underscoring their proresolving actions (Fig. 3D). Resolution of inflammation is a highly complex process and involves a delicate balance of pro- and anti-inflammatory mediators (8, 36, 40). Several reports from the literature indicate therapeutics that either impair or enhance resolution (as reviewed in ref. 3). For example, cycooxygenase and lipoxygenase inhibitors (9) and lidocaine (10) impair resolution. The most notable drugs that impair resolution are the COX-2 inhibitors that block the production of PGE

2 and PGD

2, two critical mediators that initiate resolution (41). On the other hand, aspirin or glucorticoids enhance resolution via the generation of aspirin-triggered SPMs (3) or by the endogenous production of annexin-A1, respectively (42). Furthermore, SPMs and annexin-A1 bind specific receptors and serve as agonists that trigger protective mechanisms and promote the return to homeostasis (36, 42). Restoring tissue homeostasis is vital in resolution (36). In this regard, the tissue-targeted Col-IV Ac2-26 NPs produced an ~30% inhibition of PMN infiltration into the damaged gastrocnemius (Fig. 4). Because PMNs can also

**Fig. 3.** Ac2-26 NPs are more potent than Ac2-26 and are proresolving in vivo. Zymosan (100 μg per mouse) was administered i.p., followed by i.v. injections of vehicle, empty NPs, or NPs containing Ac2-26 (Ac2-26 NP, 100 ng per mouse), scrambled Ac2-26 (Scrm Ac2-26 NP, 100 ng per mouse), or Ac2-26 native peptide (100 ng per mouse). Peritoneal exudates were harvested 4 h post zymosan initiation, and living cells were quantified using trypan blue exclusion. (A) PMNs were assessed by flow cytometry (n = 3; mean ± SEM). **P < 0.01 for zymosan vs. treatment; §P < 0.05 for Ac2-26 NP versus Ac2-26. (B) Representative dot plot of exudate cells. (Upper) Zymosan alone. (Lower) NP-treated group. (C) Peritoneal exudates were harvested 4, 12, and 24 h post zymosan treatment, and PMNs were enumerated (Scrm Ac2-26 NPs, gray; vehicle, black; Ac2-26 NPs, red). *P < 0.05, **P < 0.01 for zymosan vs. Ac2-26 NPs; §P < 0.05 for Ac2-26 NP vs. Scrm Ac2-26; $P < 0.01. (D) Resolution indices for zymosan alone (Upper) and Ac2-26 NPs (Lower) (n = 3; mean ± SEM).
have protective and restorative actions in this model, complete inhibition would be detrimental to the overall resolution of tissue inflammation (43), underscoring the fact that tempering acute inflammation, rather than blocking it, is an optimal intervention. As predicted, the Scrm Ac2-26 NPs, which served as an important control for the biophysicochemical properties of Ac2-26 NPs, did not exert anti-inflammatory or proresolving actions (Figs. 2 and 3). Thus, it is the specific sequence and structure of the native Ac2-26 peptide that confers its anti-inflammatory and proresolving properties. Results presented here are in agreement with current literature that indicates a tissue-protective role for Ac2-26 in myocardial (23) and renal ischemia-reperfusion injury (44). Notably, these studies used Ac2-26 in a much higher micromolar dose range, whereas Ac2-26 encapsulated in NPs in this study is protective against hind-limb ischemia-reperfusion injury in as low as 1 μg per mouse (Fig. 4).

Conclusions

In summary, we have developed targeted biodegradable polymeric NPs capable of releasing the anti-inflammatory annexin A1/ lipocortin A1 mimetic peptide Ac2-26 in a spatiotemporal manner. These NPs were shown to enhance resolution in vivo and blunt excessive inflammation in a hind-limb ischemia-reperfusion model. These proresolving NPs have potential for treatment of a wide array of diseases such as atherosclerosis, where excessive inflammation is an underlying pathology.

Materials and Methods

See SI Materials and Methods for detailed materials and methods. Detailed descriptions of the synthesis and characterization of all compounds can be found in SI Materials and Methods.

Development and Characterization of NPs. The required polymers (3.12 mg/mL, 3 mg polymer + 120 μg Ac2-26 peptide) and Ac2-26 or Scrm Ac2-26 (0.12 mg/mL) were dissolved in acetonitrile. All NPs contained 4% (w/v) peptide (either Ac2-26 or Scrm Ac2-26) and targeted NPs contained 5% (w/v) of the PLGA-PEG-Col IV-targeting polymer. The polymer/peptide mixture was then added dropwise to 10 mL of nuclease-free water. The NPs were stirred for 2 h and filtered through sterile 0.45-μm syringe filters (regenerated cellulose, 17 mm; Cole Palmer Instruments). The NPs were concentrated by centrifugation at 3,000 × g for 20 min using Amicon Ultra-15 centrifugal filter units (MWCO 10 kDa; Sigma-Aldrich), washed with deionized water, and resuspended in 1 mL of either nuclease-free H2O or PBS (total 3.12 mg/mL NP). For in vivo studies, NPs were resuspended in 1 mL of H2O (total 3.12 mg/mL NP) and then further diluted with PBS before injection. The NPs were diluted 20-fold in either H2O or PBS, and their size and surface charge were measured using dynamic light scattering. For TEM, a 10-μL solution of 1 mg/mL freshly prepared NPs in H2O was deposited on carbon-coated copper grids, the excess solution was blotted, and the grids were immersed in a solution of 0.75% uranyl formate stain. The stain was blotted, and the dried grids imaged within 1 h of preparation on a Tecnai G2 Spirit BioTWIN electron microscope equipped with an AMT 2k CCD camera and low-dose software (80 kV, direct magnification of 98,000×). A calibration curve of various concentrations of the Ac2-26 or scrambled Ac2-26 peptide was also generated to quantify the amount of peptide retained in the NP sample. The absorbance of the grids was measured, and the percentage of encapsulation efficiency and percentage of loading of the peptides were calculated. Peptide loading is defined as the mass fraction of peptide in the NPs, whereas encapsulation efficiency is the fraction of initial drug that is encapsulated by the NPs.

Ac2-26 NP Release Kinetics Study. To quantify the Ac2-26 release profile, 3.12 mg/mL NP samples were made in PBS, and the NPs were incubated in Eppendorfs in triplicate at 37 °C. At defined time intervals (8, 24, 48, 72, and 96 h), the NPs were removed, transferred to Amicon Ultra-15 centrifugal filter units (MWCO 10 kDa; Sigma-Aldrich), and centrifuged at 3,000 × g for 20 min. The NPs were then resuspended in PBS, and incubation was continued until the designated time point. The filtrate (10 μL) was analyzed with a nanodrop UV–Vis spectrometer, and absorbance was measured at 220 nm to determine the amount of released peptide at each time point.

In Vivo Murine Peritonitis. Female C57BL/J6 mice (6–8 wk old; Charles River Laboratories) were administered i.p. with zymosan A (100 μg per mouse; Sigma-Aldrich, St. Louis) to induce peritonitis (8, 11), followed by i.v. injection of vehicle, empty NPs, NPs containing Ac2-26 (Ac2-26 NP, 100 ng per mouse) or Scrm Ac2-26 (Scrm Ac2-26 NP, 100 ng per mouse), or Ac2-26 native peptide (100 ng per mouse). Peritoneal exudates were harvested 4, 12, or 24 h post zymosan initiation, and cells were quantified using trypan blue exclusion. Differential cell counts were assessed via flow cytometry using an LSR II flow cytometer. Cells were stained with FITC-conjugated rat anti-mouse Ly-6G (clone 1A8) or rat IgG2c,λ isotype control. All procedures were conducted in accordance with protocols approved by the Columbia University Standing Committee on Animals guidelines for animal care.

Hind-Limb Ischemia Reperfusion Injury. Hind-limb ischemia was initiated using rubber-band tourniquets placed on each hind limb as described previously (37). Mice were subjected to hind-limb ischemia for 1 h, after which the tourniquets were removed to initiate reperfusion. At the time of reperfusion, mice were administered 1 μg i.v. of Col-IV–targeted Ac2-26 NPs, Ac2-26 NPs, Col IV-targeted Scrm Ac2-26 NPs, or vehicle alone. At the end of this reperfusion period (1 h), the mice were euthanized with an overdose of anesthetic, and the gastrocnemius was quickly harvested, placed in cold lysis buffer, and homogenized. Tissue levels of myeloperoxidase (MPO) in the resulting supernatants were determined using a mouse MPO ELISA (Hycult Biotech and Cell Sciences).
Kamaly et al.

**ACKNOWLEDGMENTS.** We thank George Kurilakose (Columbia University) for technical support along with the confocal and specialized microscopy core at Columbia University’s Irving Cancer Research Center. This work was supported by a Program of Excellence in Nanotechnology Award, Contract HHSN268201000045C, from the National Heart, Lung, and Blood Institute, National Institutes of Health (NIH). This work was also supported by NIH Grant CA151884 and by a David Koch-Prostate Cancer Foundation Award in Nanotherapeutics.


